Halozyme Therapeutics (NASDAQ:HALO) Stock Rating Reaffirmed by Benchmark

Halozyme Therapeutics (NASDAQ:HALO)‘s stock had its “buy” rating reissued by stock analysts at Benchmark in a report issued on Tuesday, Benzinga reports. They currently have a $50.00 price objective on the biopharmaceutical company’s stock. Benchmark’s target price indicates a potential upside of 31.51% from the stock’s current price.

A number of other brokerages have also weighed in on HALO. The Goldman Sachs Group dropped their price objective on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating on the stock in a report on Thursday, January 18th. StockNews.com raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, February 23rd. HC Wainwright lifted their target price on Halozyme Therapeutics from $48.00 to $50.00 and gave the stock a “buy” rating in a report on Wednesday, February 21st. TD Cowen started coverage on shares of Halozyme Therapeutics in a report on Thursday, February 29th. They issued an “outperform” rating and a $54.00 price target on the stock. Finally, Morgan Stanley reduced their price target on shares of Halozyme Therapeutics from $61.00 to $59.00 and set an “overweight” rating for the company in a research report on Tuesday, December 26th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $53.29.

Halozyme Therapeutics Trading Down 0.9 %

Halozyme Therapeutics stock opened at $38.02 on Tuesday. Halozyme Therapeutics has a one year low of $29.85 and a one year high of $45.00. The stock has a market cap of $4.83 billion, a PE ratio of 18.02, a price-to-earnings-growth ratio of 0.47 and a beta of 1.25. The company has a debt-to-equity ratio of 17.89, a quick ratio of 5.50 and a current ratio of 6.64. The stock has a 50-day moving average of $39.44 and a two-hundred day moving average of $37.76.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by ($0.02). The company had revenue of $230.04 million during the quarter, compared to analysts’ expectations of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. On average, research analysts anticipate that Halozyme Therapeutics will post 3.33 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $41.64, for a total transaction of $416,400.00. Following the completion of the transaction, the senior vice president now directly owns 156,558 shares of the company’s stock, valued at approximately $6,519,075.12. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last 90 days, insiders have sold 30,000 shares of company stock worth $1,196,800. Corporate insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of institutional investors have recently modified their holdings of HALO. Hodges Capital Management Inc. raised its holdings in Halozyme Therapeutics by 61.4% in the 1st quarter. Hodges Capital Management Inc. now owns 317,045 shares of the biopharmaceutical company’s stock worth $12,897,000 after purchasing an additional 120,580 shares during the period. Brookstone Capital Management raised its stake in shares of Halozyme Therapeutics by 2.3% during the 1st quarter. Brookstone Capital Management now owns 61,710 shares of the biopharmaceutical company’s stock worth $2,510,000 after buying an additional 1,402 shares during the period. FCF Advisors LLC lifted its position in shares of Halozyme Therapeutics by 1.9% during the 1st quarter. FCF Advisors LLC now owns 21,164 shares of the biopharmaceutical company’s stock valued at $861,000 after buying an additional 391 shares in the last quarter. Congress Asset Management Co. MA grew its stake in Halozyme Therapeutics by 16.2% in the 1st quarter. Congress Asset Management Co. MA now owns 407,867 shares of the biopharmaceutical company’s stock valued at $16,592,000 after acquiring an additional 56,791 shares during the period. Finally, Park Avenue Securities LLC raised its position in Halozyme Therapeutics by 17.3% during the first quarter. Park Avenue Securities LLC now owns 8,294 shares of the biopharmaceutical company’s stock worth $337,000 after acquiring an additional 1,225 shares during the period. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.